/depts/,/depts/uwmf/,/depts/uwmf/patient-resources/,/depts/uwmf/patient-resources/social-guide/,/depts/uwmf/patient-resources/social-guide/manual/,/depts/uwmf/patient-resources/social-guide/manual/discharge-planning-and-referrals/,/depts/uwmf/patient-resources/social-guide/manual/discharge-planning-and-referrals/vad/,/depts/uwmf/patient-resources/social-guide/manual/discharge-planning-and-referrals/vad/rituximab/,

/depts/uwmf/patient-resources/social-guide/manual/discharge-planning-and-referrals/vad/rituximab/

20150126

page

100

UWHC,

Patient Services,

Departments & Programs,UW Medical Foundation,Patient Resources,Social Work Services Quick Guide,Social Work Manual,Discharge Planning and Referrals,VAD

Rituximab

Rituximab - Departments & Programs, UW Medical Foundation, Patient Resources, Social Work Services Quick Guide, Social Work Manual, Discharge Planning and Referrals, VAD

Focus

Medicare Covered Therapeutic Uses of Rituximab:

  1. Autoimmune hemolytic anemia
  2. B-cell lymphoma
  3. Chronic lymphoid leukemia, In combination for first-line treatment
  4. Chronic lymphoid leukemia, Relapsed or refractory
  5. Evans syndrome, Refractory to immunosuppressive therapy
  6. Graft-versus-host disease, chronic, Steroid-refractory
  7. Hairy cell leukemia
  8. Hodgkin's disease, CD20-positive, as monotherapy
  9. Malignant ascites - Non-Hodgkin's lymphoma
  10. Non-Hodgkin's lymphoma, Diffuse, large B-cell, CD20-positive, in combination for first-line treatment
  11. Non-Hodgkin's lymphoma, Follicular, CD20-positive, B-cell, in combination with CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy for first-line treatment
  12. Non-Hodgkin's lymphoma, Low-grade, CD20-positive, B-cell, stable or responsive to prior CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy
  13. Non-Hodgkin's lymphoma, Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell
  14. Pemphigus vulgaris, Severe
  15. Post-transplant lymphoproliferative disorder
  16. Primary cutaneous B-cell lymphoma
  17. Rheumatoid arthritis (Moderate to Severe), In combination with methotrexate, in patients who had an inadequate response to one or more tumor-necrosis-factor antagonist therapies
  18. Systemic lupus erythematosus, Refractory to immunosuppressive therapy
  19. Thrombocytopenic purpura, Immune or idiopathic
  20. Waldenstrom's macroglobulinemia
  21. Wegener's granulomatosis (Severe), Refractory, in combination with corticosteroids